Rhythm Pharmaceuticals (RYTM) Raw Materials (2022 - 2025)

Rhythm Pharmaceuticals (RYTM) has 4 years of Raw Materials data on file, last reported at $7.2 million in Q3 2025.

• Raw Materials for Q3 2025 came in at $7.2 million, up 43.01% year-over-year; the trailing twelve-month figure through Sep 2025 was $7.2 million (up 43.01% YoY), and the FY2024 annual result was $6.8 million, up 46.51% from the prior year.
• Raw Materials advanced to $7.2 million in Q3 2025 per RYTM's latest filing, from $4.5 million in the prior quarter.
• Over five years, Raw Materials peaked at $7.2 million in Q3 2025 and troughed at $2.3 million in Q2 2023.
• A 4-year average of $4.4 million and a median of $4.6 million in 2023 frame the typical range for Raw Materials.
• On a YoY basis, Raw Materials climbed as much as 82.2% in 2024 and fell as far as 31.3% in 2024.
• A 4-year view of Raw Materials shows it stood at $2.7 million in 2022, then surged by 69.91% to $4.6 million in 2023, then jumped by 46.51% to $6.8 million in 2024, then advanced by 5.95% to $7.2 million in 2025.
• Business Quant data shows RYTM's Raw Materials at $7.2 million in Q3 2025, $4.5 million in Q2 2025, and $5.0 million in Q1 2025.